טוען...

Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions

Since the year 2000, tremendous progress has been made in the understanding of castration-resistant prostate cancer (crpc), a disease state now recognized to retain androgen receptor (ar)—dependency in most cases. That understanding led to the rational design of novel therapeutic agents targeting ho...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Leibowitz–Amit, R., Joshua, A.M.
פורמט: Artigo
שפה:Inglês
יצא לאור: Multimed Inc. 2012
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3553559/
https://ncbi.nlm.nih.gov/pubmed/23355790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.19.1281
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!